Efficacy of omega-3 fatty acids on renal diseases: Are they justified?;Eficacia de los ácidos grasos omega-3 en las enfermedades renales: ¿está justificado su empleo?

Nefrologia

Volumn 25, Issue 3, 2005, Pages 221-232

  Hernández, Domingo ^a,b   Garcia S ^a   Gonzalez A ^a   Rufino, M ^a   Salido, E ^a   Torres, A ^a  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FISH OIL; LIPID; NONSTEROID ANTIINFLAMMATORY AGENT; OMEGA 3 FATTY ACID;

ANIMAL; BLOOD; CARDIOVASCULAR DISEASE; CHEMISTRY; ETHNOLOGY; GRAFT REJECTION; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMMUNOGLOBULIN A NEPHROPATHY; INDWELLING CATHETER; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; NEPHROLITHIASIS; RAT; RENAL REPLACEMENT THERAPY; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; THROMBOSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CATHETERS, INDWELLING; FATTY ACIDS, OMEGA-3; FISH OILS; GLOMERULONEPHRITIS, IGA; GRAFT REJECTION; HUMANS; HYPERTENSION; HYPERTRIGLYCERIDEMIA; KIDNEY CALCULI; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LIPIDS; RATS; RATS, INBRED SHR; RENAL DIALYSIS; THROMBOSIS;

EID: 24944471478     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Dyerberg J, Bang HO, Stoffersen E: Eicosapentanoic acid and prevention of thrombosis and atherosclerosis. Lancet 2: 117-119, 1978.
2. Kromhout D, Bosschieter EB, Coulander CL: The inverse relation between fish comsumption and 20-year mortality from heart disease. N Engl J Med 312: 1205-1209, 1985.
3. Yetiv JZ: Clinical applications of fish oil. JAMA 260: 665-670, 1988.
4. Sytkowski PA, Kannel WB, D'Agostino RB: Changes in risk factors and the decline in mortality from cardiovascular disease. The Framingham Heart Study. N Engl J Med 322: 1635-1641, 1990.
5. Gorder DD, Dolecek TA, Coleman GG, Tillotson JL, Brown HB, Lenz-Litzow K, Bartsch GE, Grandits G: Dietary intake in the Multiple Risk Factor Intervention Trial (MRFIT): nutrient and food group changes over 6 years. J Am Diet Assoc. 86: 744-751, 1986.
6. Rodríguez BL, Sharp DS, Abbott RD, Burchfiel CM, Masaki K, Chyou PH, Huang B, Yano K, Curb JD: Fish intake may limit the increase in risk of coronary heart disease morbidity and mortality among heavy smokers. The Honolulu Heart Program. Circulation 94: 952-956, 1996.
7. Hu FB, Cho E, Rexrode KM, Albert CM, Manson JE: Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women. Circulation 107: 1852-1857, 2003.
8. GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 354: 447-455, 1999.
9. Albert CM, Hennekens CH, O'Donnell CJ, Ajani UA, Carey VJ, Willett WC, Ruskin JN, Manson JE: Fish consumption and risk of sudden cardiac death. JAMA 279: 23-28, 1998.
10. Oomen CM, Feskens EJ, Rasanen L, Fidanza F, Nissinen AM, Menotti A, Kok FJ, Kromhout D: Fish consumption and coronary heart disease mortality in Finland, Italy, and The Netherlands. Am J Epidemiol 151: 999-1006, 2000.
11. Harper CR, Jacobson TA: Beyond the Mediterranean diet: the role of omega-3 fatty acids in prevention of coronary heart disease. Prev Cardiol 6: 136-146, 2003.
12. Schmidt EB: n-3 fatty acids and the risk of coronary heart disease. Dan Med Bull 44: 1-22, 1997.
13. Roche HM: Unsaturated fatty acids. Proc Nutr Soc 58: 397-401, 1999.
14. Simopoulos AP: Essential fatty acids in health and chronic disease. Am J Clin Nutr 70 (3 Supl.): 560S-569S, 1999.
15. De Caterina R, Endres S, Kristensen SD, Schmidt EB: n-3 fatty acids and renal diseases. Am J Kidney Dis 24: 397-415, 1994.
16. Ferretti A, Schoene NW, Flanagan VP: Identification and quantification of prostaglandin E3 in renal medullary tissue of three strains of rats fed fish oil. Lipids 16: 800-804, 1981.
17. Schoene NW, Ferretti A, Fiore D: Production of prostaglandins in homogenates of kidney medullae and cortices of spontaneously hypertensive rats fed menhaden oil. Lipids 16: 866-869, 1981.
18. Baud L, Sraer J, Pérez J, Nivez MP, Ardaillou R: Leukotriene C4 binds to human glomerular epithelial cells and promotes their proliferation in vitro. J Clin Invest 76: 374-377, 1985.
19. Lewis RA, Austen KF: The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. J Clin Invest 73: 889-897, 1984.
20. Endres S, Ghorbani R, Kelley VE, Georgilis K, Lonnemann G, Van der Meer JW, Cannon JG, Rogers TS, Klempner MS, Weber PC y cols.: The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells. N Engl J Med 320: 265-271, 1989.
21. Meydani SN, Endres S, Woods MM, Goldin BR, Soo C, Morrill-Labrode A, Dinarello CA, Gorbach SL: Oral (n-3) fatty acid supplementation suppresses cytokine production and lymphocyte proliferation: comparison between young and older women. J Nutr 121: 547-555, 1991.
22. Endres S, Meydani SN, Ghorbani R, Schindler R, Dinarello CA: Dietary supplementation with n-3 fatty acids suppresses interleukin-2 production and mononuclear cell proliferation. J Leukoc Biol 54: 599-603, 1993.
23. Lee TH, Hoover RL, Williams JD, Sperling RI, Ravalese J 3rd, Spur BW, Robinson DR, Corey EJ, Lewis RA, Austen KF: Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. N Engl J Med 312: 1217-1224, 1985.
24. Schmidt EB, Dyerberg J: n-3 fatty acids and leucocytes. J Intern Med Suppl 225: 151-158, 1989.
25. Schmidt EB, Pedersen JO, Ekelund S, Grunnet N, Jersild C, Dyerberg J: Cod liver oil inhibits neutrophil and monocyte chemotaxis in healthy males. Atherosclerosis 77: 53-57, 1989.
26. Phillipson BE, Rothrock DW, Connor WE, Harris WS, Illingworth DR: Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 312: 1210-1216, 1985.
27. Guijarro C, Massy ZA, Kasiske BL: Clinical correlation between renal allograft failure and hyperlipidemia. Kidney Int Suppl. 52: S56-S59, 1995.
28. Fox PL, DiCorleto PE: Fish oils inhibit endothelial cell production of platelet-derived growth factor-like protein. Science 241: 453-456, 1988.
29. Shiina T, Terano T, Saito J, Tamura Y, Yoshida S. Eicosapentaenoic acid and docosahexaenoic acid suppress the proliferation of vascular smooth muscle cells. Atherosclerosis 104: 95-103, 1993.
30. Harker LA, Kelly AB, Hanson SR, Krupski W, Bass A, Osterud B, FitzGerald GA, Goodnight SH, Connor WE: Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates. Circulation 87: 1017-1029, 1993.
31. Boulanger C, Schini VB, Hendrickson H, Vanhoutte PM: Chronic exposure of cultured endothelial cells to eicosapentaenoic acid potentiates the release of endothelium-derived relaxing factor(s). Br J Pharmacol 99: 176-80, 1990.
32. Vanhoutte PM, Shimokawa H, Boulanger C: Fish oil and the platelet-blood vessel wall interaction. World Rev Nutr Diet 66: 233-244, 1991.
33. Kang JX, Leaf A: Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 71 (Supl. 1): 202S-207S, 2000.
34. Endres S, De Caterina R, Schmidt EB, Kristensen SD: n-3 polyunsaturated fatty acids: update 1995. Eur J Clin Invest 25: 629-638, 1995.
35. Jump DB: Fatty acid regulation of gene transcription. Crit Rev Clin Lab Sci 41: 41-78, 2004.
36. Donadio JV, Grande JP: IgA nephropathy. N Engl J Med 347: 738-748, 2002.
37. Donadio JV Jr, Bergstralh EJ, Offord KP, Spencer DC, Holley KE: A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group. N Engl J Med 331: 1194-1199, 1994.
38. Donadio JV Jr, Larson TS, Bergstralh EJ, Grande JP: A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy J Am Soc Nephrol 12: 791-799, 2001.
39. Donadio JV, Grande JP: The role of fish oil/omega-3 fatty acids in the treatment of IgA nephropathy. Semin Nephrol 24: 225-43, 2004.
40. Donadio JV Jr, Grande JP, Bergstralh EJ, Dart RA, Larson TS, Spencer DC: The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 10: 1772-1777, 1999.
41. Strippoli GF, Manno C, Schena FP: An «evidence-based» survey of therapeutic options for IgA nephropathy: assessment and criticism. Am J Kidney Dis 41: 1129-1139, 2003.
42. Bilo HJ, Homan van der Heide JJ, Gans RO, Donker AJ: Omega-3 polyunsaturated fatty acids in chronic renal insufficiency. Nephron 57: 385-393, 1991.
43. De Caterina R, Caprioli R, Giannessi D, Sicari R, Galli C, Lazzerini G, Bernini W, Carr L, Rindi P: n-3 fatty acids reduce proteinuria in patients with chronic glomerular disease. Kidney Int 44: 843-850, 1993.
44. Grande JP, Walker HJ, Holub BJ, Warner GM, Keller DM, Haugen JD, Donadio JV Jr, Dousa TP: Suppressive effects of fish oil on mesangial cell proliferation in vitro and in vivo. Kidney Int 57: 1027-1040, 2000.
45. Clark WF, Parbtani A, Huff MW, Reid B, Holub BJ, Falardeau P: Omega-3 fatty acid dietary supplementation in systemic lupus erythematosus. Kidney Int 36: 653-660, 1989.
46. Chandrasekar B, Troyer DA, Venkatraman JT, Fernandes G: Dietary omega-3 lipids delay the onset and progression of autoimmune lupus nephritis by inhibiting transforming growth factor beta mRNA and protein expression. J Autoimmun 8: 381-393, 1995.
47. Bhattacharya A, Lawrence RA, Krishnan A, Zaman K, Sun D, Fernandes G: Effect of dietary n-3 and n-6 oils with and without food restriction on activity of antioxidant enzymes and lipid peroxidation in livers of cyclophosphamide treated autoimmune-prone NZB/W female mice. J Am Coll Nutr 22: 388-99, 2003.
48. Clark WF, Parbtani A, Naylor CD, Levinton CM, Muirhead N, Spanner E, Huff MW, Philbrick DJ, Holub BJ: Fish oil in lupus nephritis: clinical findings and methodological implications. Kidney Int 44: 75-86, 1993.
49. Clark WF, Parbtani A: Omega-3 fatty acid supplementation in clinical and experimental lupus nephritis. Am J Kidney Dis 23: 644-647, 1994.
50. Westberg G, Tarkowski A: Effect of MaxEPA in patients with SLE. A double-blind, crossover study. Scand J Rheumatol 19: 137-143, 1990.
51. Duffy EM, Meenagh GK, McMillan SA, Strain JJ, Hannigan BM, Bell AL: The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus. J Rheumatol 31: 1551-1556, 2004.
52. Harris WS: n-3 fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65(5 Supl.): 1645S-1654S, 1997.
53. Nordoy A: Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease. Minerva Med 93: 357-363, 2002.
54. Sahadevan M, Kasiske BL: Hyperlipidemia in kidney disease: causes and consequences. Curr Opin Nephrol Hypertens 11: 323-329, 2002.
55. Svensson M, Christensen JH, Solling J, Schmidt EB: The effect of n-3 fatty acids on plasma lipids and lipoproteins and blood pressure in patients with CRF. Am J Kidney Dis 44: 77-83, 2004.
56. rd, Seidler AJ, Whelton PK: Does supplementation of diet with «fish oil» reduce blood pressure? A meta-analysis of controlled clinical trials. Arch Intern Med 153: 1429-38, 1993.
57. Morris MC, Sacks F, Rosner B: Does fish oil lower blood pressure? A meta-analysis of controlled trials. Circulation 88: 523-533, 1993.
58. Geleijnse JM, Giltay EJ, Grobbee DE, Donders AR, Kok FJ: Blood pressure response to fish oil supplementation: metaregression analysis of randomized trials. J Hypertens 20: 1493-1499, 2002.
59. Lungershausen YK, Abbey M, Nestel PJ, Howe PR: Reduction of blood pressure and plasma triglycerides by omega-3 fatty acids in treated hypertensives. J Hypertens 12: 1041-1045, 1994.
60. Singer P, Melzer S, Goschel M, Augustin S: Fish oil amplifies the effect of propranolol in mild essential hypertension, Hypertension 16: 682-691, 1990.
61. Levin A, Foley RN: Cardiovascular disease in chronic renal insufficiency. Am J Kidney Dis 36 (Supl. 3): S24-30, 2000.
62. Christensen JH, Christensen MS, Dyerberg J, Schmidt EB: Heart rate variability and fatty acid content of blood cell membranes: a dose-response study with n-3 fatty acids. Am J Clin Nutr 70: 331-337, 1999.
63. Calder PC: n-3 Fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci (Lond) 107: 1-11, 2004.
64. Wang HH, Hung TM, Wei J, Chiang AN: Fish oil increases antioxidant enzyme activities in macrophages and reduces atherosclerotic lesions in apoE-knockout mice. Cardiovasc Res 61: 169-76, 2004.
65. Weiner BH, Ockene IS, Levine PH, Cuenoud HF, Fisher M, Johnson BF, Daoud AS, Jarmolych J, Hosmer D, Johnson MH y cols.: Inhibition of atherosclerosis by cod-liver oil in a hyperlipidemic swine model. N Engl J Med 315: 841-846, 1986.
66. Landymore RW, Manku MS, Tan M, MacAulay MA, Sheridan B: Effects of low-dose marine oils on intimal hyperplasia in autologous vein grafts. J Thorac Cardiovasc Surg 98 (Pt 1):788-791, 1989.
67. Sarris GE, Fann JI, Sokoloff MH, Smith DL, Loveday M, Kosek JC, Stephens RJ, Cooper AD, May K, Willis AL y cols.: Mechanisms responsible for inhibition of vein-graft arteriosclerosis by fish oil. Circulation 80 (3 Pt 1): I109-123, 1989.
68. Culp BR, Lands WE, Lucches BR, Pitt B, Romson J: The effect of dietary supplementation of fish oil on experimental myocardial infarction. Prostaglandins 20: 1021-1031, 1980.
69. Hock CE, Beck LD, Bodine RC, Reibel DK: Influence of dietary n-3 fatty acids on myocardial ischemia and reperfusion. Am J Physiol 259 (5 Pt 2): H1518-26, 1990.
70. Aguila MB, Sa Silva SP, Pinheiro AR, Mandarim-de-Lacerda CA: Effects of long-ter, intake of edible oils on hypertension and myocardial and aortic remodelling in spontaneously hypertensive rats. J Hypertens 22: 921-929, 2004.
71. Eritsland J, Arnesen H, Gronseth K, Fjeld NB, Abdelnoor M: Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency. Am J Cardiol 77: 31-36, 1996.
72. Erkkila AT, Lehto S, Pyorala K, Uusitupa MI: n-3 Fatty acids and 5-y risks of death and cardiovascular disease events in patients with coronary artery disease. Am J Clin Nutr 78: 65-71, 2003.
73. Burr ML, Fehily AM, Gilbert JF Rogers S, Holliday RM, Sweetnam PM, Elwood PC, Deadman NM: Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfraction: Diet and Reinfarction Trial (DART). Lancet 2: 757-761, 1989.
74. De Lorgeril M, Renaud S, Memelle N, Salen P, Martin JL, Monjaud I, Guidollet J, Touboul P, Delaye J: Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 343: 1454-1459, 1994.
75. Bucher HC, Hengstler P, Schindler C, Meier G: N-3 polyunsaturated fatty acids in coronary heart disease: a metaanalysis of randomized controlled trials. Am J Med 12: 298-304, 2002.
76. Whelton SP, He J, Whelton PK, Muntner P: Meta-analysis of observational studies on fish intake and coronary heart disease. Am J Cardiol 93: 1119-1123, 2004.
77. Leaf A, Kang JX, Xiao YF, Billman GE: Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 fish oils. Circulation 107 (21): 2646-52, 2003.
78. Miller PE, Carlaton D, Deirhoi MH, Redden DT, Allon M: Natural history of arteriovenous graft in hemodialysis patients. Am J Kidney Dis 36: 68-74, 2000.
79. Schmitz PG, McCloud LK, Reikes ST, Leonard CL, Gellens ME: Prophylaxis of hemodialysis graft thrombosis with fish oil: double-blind, randomised, prospective trial. Schmitz. J Am Soc Nephrol 13: 184-190, 2002.
80. Jensen T, Stender S, Goldstein K, Holmer G, Deckert T: Partial normalization by duetary cod-liver oil of increased microvascular albumin leakage in patients with insulin-dependent diabetes and albuminuria. N Engl J Med 321: 1572-1577, 1989.
81. Hamazaki T, Takazakura E, Osawa K, Urakaze M, Yano S: Reduction in microalbuminuria in diabetic by eicosapentaenoic acid ethyl esters. Lipids 25: 541-545, 1990.
82. Rossing P, Hansen BV, Nielsen FS, Myrup B, Holmer G, Parving HH: Fish oil in diabetic nephropathy. Diabetes Care 19: 1214-1219, 1996.
83. Myrup B, Rossing P, Jensen T, Parving HH, Holmer G, Gram J, Klu Jespersen J: Lack of effect of fish oil supplemtation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy. Scand J Clin Lab Invest 61: 349-356, 2001.
84. Buck AC, Davies RL, Harrison T: The protective role of eicosapentaenoic acid [EPA] in the pathogenesis of nephrolithiasis J Urol 146: 188-194, 1991.
85. Yasui T, Tanaka H, Fujita K, Iguchi M, Kohri K: Effects of eicosapentaenoic acid on urinary calcium excretion in calcium stone formers. Eur Urol 39: 580-585, 2001.
86. Baggio B, Budakovic A, Priante G, Gambaro G, Manzato E, Khan S: Dietary fatty acid supplementation modulates the urinary excretion of calcium and oxalate in the rat. Insight into calcium lithogenesis. Nephron 91: 486-491, 2002.
87. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, T Bustami R, Dyke DB: Immunosuppression: practice and trends. Am J Transplant 4 (Supl. 9): 38-53, 2004.
88. Thervet E, Martínez F, Legendre C: Benefit-risk assessment of ciclosporin withdrawal in renal transplant recipients. Drug Saf 27: 457-476, 2004.
89. Ventura HO, Milani RV, Lavie CJ, Smart FW, Stapleton DD, Toups TS, Price HL: Cyclosporine-induced hypertension. Efficacy of ω-3 fatty acids in patients after cardiac transplantation. Circulation 88 (part 2): 281-285, 1993.
90. Artz MA, Boots JM, Ligtenberg G, Roodnat JI, Christiaans MH, Vos PF, Moons P, Borm G, Hilbrands LB: Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile. Am J Transplant 4: 937-945, 2004.
91. Feutren G, Mihatsch MJ: Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 326: 1654-1660, 1992.
92. Perico N, Pasini M, Gaspari F, Abbate M, Remuzzi G: Co'participation of thromboxane A2 and leukotriene C4 and D4 in mediating cyclosporine-induced acute renal failure. Transplantation 52: 873-878, 1991.
93. Bennet WM, Elzinga L, Kelley VE: Pathophysiology of cyclosporine nephrotoxicity: role of eicosanoids. Transplant Proc 20: 628-633, 1988.
94. Rogers TS, Elzinga L, Bennet WM, Kelley VE: Selective enhancement of thromboxane in macrophages and kidneys in cyclosporine-induced nephrotoxicity. Dietary protection by fish oil. Transplantation 45: 153-156, 1988.
95. Elzinga L, Kelley VE, Houghton DC, Bennet WM: Fish oil vehicle for cyclosporine lowers renal thromboxanes and reduces experimental nephrotoxicity. Transplant Proc 19: 1403-1406, 1987.
96. Elzinga L, Kelley VE, Houghton DC, Bennet WM: Modification of experimental nephrotoxicity with fish oil as the vehicle for cyclosporine. Transplantation 43: 271-274, 1987.
97. Mills DE, Ward RP, McCutcheon D, Dixon H, Ly H, Scholey J: Attenuation of cyclosporine-induced hypertension by dietary fatty acids in the borderline hypertensive rat. Transplantation 53: 649-655, 1992.
98. Donadio JV: n-3 Fatty acids and their role in nephrologic practice. Curr Opin Nephrol Hypertens 10: 639-642, 2001.
99. Homan van der Heide JJ, Bilo HJG, Tegzess AM, Donker AJM: The effects of dietary supplementation with fish oil on renal fucntion in cyclosporine-treated renal transplant recipients. Transplantation 49: 523-527, 1990.
100. Bethoux FC, Guerin C, Burgard G, Berthoux P, Alamartine E: One-year randomized controlled trial with omega-3 fatty acid-fish oil in clinical renal transplantation. Transplant Proc 24: 2578-2582, 1992.
101. Sweny P, Wheeler DC, Luis SF, Amin NS, Barradas MA, Jeremy JY, Mikhailidis DP, Varghese Z, Fernando ON, Moorhead JF: Dietary fish oil supplements preserve renal function in renal transplant recipients with chronic vascular rejection. Nephrol Dial Transplant 4: 1070-1075, 1989.
102. Kooijmans-Coutinho MF, Rischen-Vos J, Hermans J, Arndt JW, Van der Woude FJ: Dietary fish oil in renal transplant recipients treated with cyclosporine-A: no beneficial effects shown. J Am Soc Nephrol 7: 513-518, 1996.
103. Hernández D, Guerra R, Milena A, Torres A, García S, García C, Abreu P, González A, Gómez MA, Rufino M, González-Posada J, Lorenzo V, Salido E. Nephrol Dial Transplant 17: 897-904, 2002.
104. Hansen JM, Lokkegaard H, Hoy CE, Fogh-Andersen N, Olsen NV, Strandgaard S: No effect of dietary fish oil on renal hemodynamics, tubular function and renal functional reserve in long-term renal transplant recipients. J Am Soc Nephrol 5: 1434-1440, 1995.
105. Vanderbroecke C, Caillat-Zucman S, Legendre C, Noel LH, Kreis H, Woodrow D, Bach JF, Tovey MG: Differential in situ expression of cytokines in renal allograft rejection. Transplantation 51: 602-609, 1991.
106. Noronha IL, Krüger C, Andrassy K, Ritz E, Waldherr R: In situ production of TNF-α, IL-β and IL-2R in ANCA-positive glomerulonephritis. Kidney Int 43: 682-692, 1993.
107. Pang G, Couch L, Clancy R, Cripps A: GM-CSF, IL-1α, IL-1β, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1α and TNF-α. Clin Exp Immunol 96: 437-443, 1994.
108. Yard BA, Kooymans-Couthino M, Paape ME, Bruijn JA, Daha MR, Van Es LA, Van der Woude FJ: Analysis of cytokine production by graft-infiltriting cells isolated from ejection renal allografts. Transplantation 57: 153-155, 1994.
109. Dallman MJ, Roake J, Hughes D, Toogood G, Morris PJ: Sequential analysis of IL-2 gene transcription in renal transplantation. Transplantation 53: 683-685, 1992.
110. Noronha IL, Eberlein-Gonska M, Hartley B, Stephens S, Cameron JS, Waldheer R: In situ expression of tumor necrosis factor-α, interferon-γ, and interleukin-2 receptors in renal allograft biopsies. Transplantation 54: 1017-1024, 1992.
111. Ford HR, Hoffman RA, Tweardy DJ, Kispert P, Wang S, Simmons RL: Evidence that production of interleukin 6 within the rejecting allograft coincides with cytotoxic T lymphocyte development. Transplantation 51: 656-661, 1991.
112. Noronha IL, Hartley B, Cameron JS, Waldherr R: Detection of IL-1β and TNF-α message and protein in renal allograft biopsies. Transplantation 56: 1026-1029, 1993.
113. De Pablo MA, De Cienfuegos GA: Modulatory effects of dietary lipids on immune system functions. Immunol Cell Biol 78: 31-39, 2000.
114. Homan van de Heide JJ, Bilo HJG, Donker JM, Wilmink JM, Tegzess AM: Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. N Engl J Med 329: 769-773, 1993.
115. Kasiske BL: Epidemiology of cardiovascular disease after renal transplantation. Transplantation 72 (Supl. 6): S5-8, 2001.
116. Kasiske BL, Chakkera HA, Roel J: Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 11: 1735-1743, 2000.
117. Margreiter R: European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 359: 741-746, 2002.
118. Hernández D, Alvarez A, Torres A, Oppenheimer F, Cobo M, González-Posada JM, Jiménez A, Lorenzo V, Torregrosa V: Cardiovascular risk profile in non-diabetic renal transplant patients: cyclosporine versus tacrolimus. Transplant Proc 35: 1727-1729, 2003.
119. Chueh SC, Kahan BD: Dyslipidemia in renal transplant recipients treated with a sirolimus and cyclosporine-based immunosuppressive regimen: incidence, risk factors, progression, and prognosis. Transplantation 76: 375-382, 2003.
120. Matas AJ, Payne WD, Sutherland DE, Humar A, Gruessner RW, Kandaswamy R, Dunn DL, Gillingham KJ, Najarian JS: 2,500 living donor kidney transplants: a single-center experience. Ann Surg 234: 149-164, 2001.
121. Halloran PF, Melk A, Barth C: Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 10: 167-181, 1999.
122. Moore R, Hernández D, Valantine H: Calcineurin inhibitors and post-transplant hyperlipidaemias. Drug Saf 24: 755-766, 2001.
123. Deters M, Kirchner G, Koal T, Resch K, Kaever V: Everolimus/ cyclosporine interactions on bile flow and biliary excretion of bile salts and cholesterol in rats. Dig Dis Sci 49: 30-37, 2004.
124. Castro R, Queiros J, Fonseca I, Pimentel JP, Henriques AC, Sarmento AM, Guimaraes S, Pereira MC: Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil. Nephrol Dial Transplant 12: 2140-2143, 1997.
125. Rodríguez A, De Bonis E, González-Posada JM, Torres A, Pérez L, Domínguez Ml, Lorenzo V, Hernández D: Tratamiento de la dislipemia postrasplante renal: efecto comparativo de la lovastatina y ácidos grasos poliinsaturados omega-3. Nefrología 17: 49-54, 1997.
126. Fernandes G, Chandrasekar B, Luan X, Troyer DA: Modulation of antioxidant enzymes and programmed cell death by n-3 fatty acids. Lipids 31 (Supl.): S91-96, 1996.